LUND, Sweden, April 22, 2020 /PRNewswire/ -- Immunovia invites
to a teleconference (in English) for investors, analysts and media
on Tuesday, April 28th,
2020 at 16:30 CET. Immunovia will
publish the company's interim report on April 28th, 2020 at 16:00 CET.
Mats Grahn, CEO will present
Immunovia and comment on the interim report for the period January
- March 2020 followed by a Q&A
session.
Please call in a few minutes in advance. To attend, please
dial-in at one of the numbers below and provide the conference code
Immunovia to the operator:
Conference Numbers:
Sweden: +46-(0)-8-50520424
United Sates: +1-212-999-6659
France: +33-(0)-1-7099-4740
Denmark: +45-3271-4573
Germany:
+49-(0)-69-7104-45598
Spain: +34-91-788-9854
Netherlands:
+31-(0)-20-794-8426
Norway: +47-2-156-3318
Austria: +43-(0)-12530807
Switzerland:
+41-(0)-43-456-9986
UK (standard international access): +44-(0)-20-3003-2666
Conference Code: (to provide to the operator)
Immunovia
Immunovia Webcast:
https://channel.royalcast.com/webcast/immunovia/20200401_1/
There will be an MP3-file available at Immunovia's webpage under
Investors/Financial Reports
(http://immunovia.com/investors/financial-reports/) for those who
want to listen to the telephone conference afterwards. The file
will be available within two hours after the conference has
ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-interim-report-january---march-2020-on-april-28--2020,c3094531
The following files are available for download:
https://mb.cision.com/Main/13121/3094531/1234023.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/invitation-to-presentation-of-immunovias-interim-report-january---march-2020-on-april-28-2020-301045422.html
SOURCE Immunovia AB